Two Positive Studies of Genentech's Atezolizumab in Specific Type of Lung Cancer Presented at 2015 ECC

Genentech, a member of the Roche Group RHHBY, today announced positive results from two Phase II studies that evaluated the investigational cancer immunotherapy atezolizumab (anti-PDL1; MPDL3280A) in people with advanced non-small cell lung cancer (NSCLC). In the randomized Phase II study, POPLAR, atezolizumab met its primary endpoint and showed a statistically significant survival benefit compared to chemotherapy (HR=0.54; p=0.014) in people with recurrent NSCLC whose tumors expressed medium and high levels of PD-L1, which corresponded with people living 7.7 months longer than people who received docetaxel chemotherapy. A separate, single-arm Phase II study, BIRCH, met its primary endpoint and showed that atezolizumab shrank tumors (objective response rate, ORR) in up to 27 percent See full press release